Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016, Article ID 7034167, 3 pages
http://dx.doi.org/10.1155/2016/7034167
Case Report

Paraneoplastic Syndrome in Splenic Marginal Zone Lymphoma: A Rare Phenomenon of Paraplegia as an Atypical Presenting Manifestation

Hematology/Oncology Department, Henry Ford Hospital, Detroit, MI 48202, USA

Received 5 January 2016; Revised 15 March 2016; Accepted 28 March 2016

Academic Editor: Marie-Christine Kyrtsonis

Copyright © 2016 Jessica Schering and Vijayalakshmi Donthireddy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Thieblemont, “Clinical presentation and management of marginal zone lymphomas,” Hematology/The Education Program of the American Society of Hematology, pp. 307–313, 2005. View at Google Scholar
  2. L. Liu, H. Wang, Y. Chen, L. Rustveld, G. Liu, and X. L. Du, “Splenic marginal zone lymphoma: a population-based study on the 2001–2008 incidence and survival in the United States,” Leukemia and Lymphoma, vol. 54, no. 7, pp. 1380–1386, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Delsol, J. Diebold, P. G. Isaacson et al., “Pathology of the spleen: report on the workshop of the VIIIth meeting of the European Association for Haematopathology, Paris 1996,” Histopathology, vol. 32, no. 2, pp. 172–179, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Matutes, R. Morilla, K. Owusu-Ankomah, A. Houlihan, and D. Catovsky, “The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders,” Blood, vol. 83, no. 6, pp. 1558–1562, 1994. View at Google Scholar · View at Scopus
  5. E. Matutes, D. Oscier, C. Montalban et al., “Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria,” Leukemia, vol. 22, no. 3, pp. 487–495, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Thieblemont, P. Felman, F. Berger et al., “Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients,” Clinical Lymphoma, vol. 3, no. 1, pp. 41–47, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Milosevic, M. Todorovic, B. Balint et al., “Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma,” World Journal of Gastroenterology, vol. 15, no. 32, pp. 4009–4015, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Kalpadakis, G. A. Pangalis, T. P. Vassilakopoulos, S. Sachanas, and M. K. Angelopoulou, “Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?” Leukemia and Lymphoma, vol. 55, no. 7, pp. 1463–1470, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Tsimberidou, D. Catovsky, E. Schlette et al., “Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone,” Cancer, vol. 107, no. 1, pp. 125–135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Bennett, K. Sharma, S. Yegena, I. Gavish, H. P. Dave, and G. P. Schechter, “Rituximab monotherapy for splenic marginal zone lymphoma,” Haematologica, vol. 90, no. 6, pp. 856–858, 2005. View at Google Scholar · View at Scopus
  11. C. Kalpadakis, G. A. Pangalis, M. N. Dimopoulou et al., “Rituximab monotherapy is highly effective in splenic marginal zone lymphoma,” Hematological Oncology, vol. 25, no. 3, pp. 127–131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Else, A. Marín-Niebla, F. de la Cruz et al., “Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma,” British Journal of Haematology, vol. 159, no. 3, pp. 322–328, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. J. Rummel, N. Niederle, G. Maschmeyer et al., “Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial,” The Lancet, vol. 381, no. 9873, pp. 1203–1210, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Iannitto, A. Ambrosetti, E. Ammatuna et al., “Splenic marginal zone lymphoma with or without villous lymphocytes: hematologic findings and outcomes in a series of 57 patients,” Cancer, vol. 101, no. 9, pp. 2050–2057, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Mollejo, E. Lloret, J. Menárguez, M. A. Piris, and P. G. Isaacson, “Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features,” American Journal of Surgical Pathology, vol. 21, no. 7, pp. 772–780, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Audouin, A. Le Tourneau, T. Molina et al., “Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes,” British Journal of Haematology, vol. 122, no. 3, pp. 404–412, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. D. W. Anderson and A. Borsaru, “Case report: lymphoma-related resolving paraneoplastic myelopathy with MRI correlation,” The British Journal of Radiology, vol. 81, no. 964, pp. e103–e105, 2008. View at Publisher · View at Google Scholar · View at Scopus